Clinical trial
BMS 247550 to Treat Kidney Cancer
NCT00030992 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00030992 |
|---|---|
| Title | BMS 247550 to Treat Kidney Cancer |
| Official title | A Phase II Clinical Trial of BMS-247550 (NSC 710428), an Epothilone B Analog, in Renal Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | BMS-247550, Ranitidine, Diphenhydramine |
| Enrollment | 102 |
| Start date | Feb 1, 2002 |
| Primary completion | Jan 1, 2009 |
| Completion | Jun 1, 2012 |
| First posted | Feb 21, 2002 |
| Last update posted | Aug 20, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: